These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib. Campbell RA; Sanchez E; Steinberg J; Shalitin D; Li ZW; Chen H; Berenson JR Eur J Haematol; 2010 Mar; 84(3):201-11. PubMed ID: 19929977 [TBL] [Abstract][Full Text] [Related]
3. Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma. Kaiser M; Lamottke B; Mieth M; Jensen MR; Quadt C; Garcia-Echeverria C; Atadja P; Heider U; von Metzler I; Türkmen S; Sezer O Eur J Haematol; 2010 Apr; 84(4):337-44. PubMed ID: 20028416 [TBL] [Abstract][Full Text] [Related]
4. A pivotal role for Mcl-1 in Bortezomib-induced apoptosis. Podar K; Gouill SL; Zhang J; Opferman JT; Zorn E; Tai YT; Hideshima T; Amiot M; Chauhan D; Harousseau JL; Anderson KC Oncogene; 2008 Jan; 27(6):721-31. PubMed ID: 17653083 [TBL] [Abstract][Full Text] [Related]
5. Inhibitors of protein kinase C sensitise multiple myeloma cells to common genotoxic drugs. Baumann P; Armann J; Mandl-Weber S; Grün G; Oduncu F; Schmidmaier R Eur J Haematol; 2008 Jan; 80(1):37-45. PubMed ID: 18028419 [TBL] [Abstract][Full Text] [Related]
6. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma. Noborio-Hatano K; Kikuchi J; Takatoku M; Shimizu R; Wada T; Ueda M; Nobuyoshi M; Oh I; Sato K; Suzuki T; Ozaki K; Mori M; Nagai T; Muroi K; Kano Y; Furukawa Y; Ozawa K Oncogene; 2009 Jan; 28(2):231-42. PubMed ID: 18850009 [TBL] [Abstract][Full Text] [Related]
7. The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma. Baumann P; Mandl-Weber S; Oduncu F; Schmidmaier R Exp Cell Res; 2009 Feb; 315(3):485-97. PubMed ID: 19071109 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma. Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159 [TBL] [Abstract][Full Text] [Related]
9. Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma. von Metzler I; Heider U; Mieth M; Lamottke B; Kaiser M; Jakob C; Sezer O Exp Cell Res; 2009 Aug; 315(14):2471-8. PubMed ID: 19410573 [TBL] [Abstract][Full Text] [Related]
10. Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis. Balsas P; López-Royuela N; Galán-Malo P; Anel A; Marzo I; Naval J Biochem Pharmacol; 2009 Mar; 77(5):804-12. PubMed ID: 19100720 [TBL] [Abstract][Full Text] [Related]
11. Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions. Boissy P; Andersen TL; Lund T; Kupisiewicz K; Plesner T; Delaissé JM Leuk Res; 2008 Nov; 32(11):1661-8. PubMed ID: 18394701 [TBL] [Abstract][Full Text] [Related]
12. Blockage of interleukin-6 signaling with 6-amino-4-quinazoline synergistically induces the inhibitory effect of bortezomib in human U266 cells. Park J; Ahn KS; Bae EK; Kim BS; Kim BK; Lee YY; Yoon SS Anticancer Drugs; 2008 Sep; 19(8):777-82. PubMed ID: 18690088 [TBL] [Abstract][Full Text] [Related]
13. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. Hazlehurst LA; Enkemann SA; Beam CA; Argilagos RF; Painter J; Shain KH; Saporta S; Boulware D; Moscinski L; Alsina M; Dalton WS Cancer Res; 2003 Nov; 63(22):7900-6. PubMed ID: 14633719 [TBL] [Abstract][Full Text] [Related]
14. Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity. Montero JC; López-Pérez R; San Miguel JF; Pandiella A Haematologica; 2008 Jun; 93(6):851-9. PubMed ID: 18443272 [TBL] [Abstract][Full Text] [Related]
15. Targeting NF-kappaB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growth. Jourdan M; Moreaux J; Vos JD; Hose D; Mahtouk K; Abouladze M; Robert N; Baudard M; Rème T; Romanelli A; Goldschmidt H; Rossi JF; Dreano M; Klein B Br J Haematol; 2007 Jul; 138(2):160-8. PubMed ID: 17542984 [TBL] [Abstract][Full Text] [Related]
16. Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myeloma. Bisping G; Wenning D; Kropff M; Gustavus D; Müller-Tidow C; Stelljes M; Munzert G; Hilberg F; Roth GJ; Stefanic M; Volpert S; Mesters RM; Berdel WE; Kienast J Clin Cancer Res; 2009 Jan; 15(2):520-31. PubMed ID: 19147757 [TBL] [Abstract][Full Text] [Related]
17. Triptolide overcomes dexamethasone resistance and enhanced PS-341-induced apoptosis via PI3k/Akt/NF-kappaB pathways in human multiple myeloma cells. Yang M; Huang J; Pan HZ; Jin J Int J Mol Med; 2008 Oct; 22(4):489-96. PubMed ID: 18813856 [TBL] [Abstract][Full Text] [Related]
18. Interleukin-6 affects melphalan-induced DNA damage and repair in human multiple myeloma cells. Efferth T; Fabry U; Osieka R Anticancer Res; 2002; 22(1A):231-4. PubMed ID: 12017294 [TBL] [Abstract][Full Text] [Related]
19. Bortezomib in the front-line treatment of multiple myeloma. Richardson PG; Mitsiades C; Schlossman R; Ghobrial I; Hideshima T; Munshi N; Anderson KC Expert Rev Anticancer Ther; 2008 Jul; 8(7):1053-72. PubMed ID: 18588451 [TBL] [Abstract][Full Text] [Related]
20. NF-κB localization in multiple myeloma plasma cells and mesenchymal cells. Conticello C; Giuffrida R; Adamo L; Anastasi G; Martinetti D; Salomone E; Colarossi C; Amato G; Gorgone A; Romano A; Iannolo G; De Maria R; Giustolisi R; Gulisano M; Di Raimondo F Leuk Res; 2011 Jan; 35(1):52-60. PubMed ID: 20674018 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]